Athena Global Technologies Ltd

AGM Details

• Date, time, mode: 30 September 2026 at 01:30 P.M. IST via VC/OAVM.
• Meeting duration: began 01:30 P.M., concluded 01:43 P.M. IST.
• Attendees included directors, KMP, statutory auditors, and Scrutinizer via VC.

Key Resolutions

• Ordinary: Adoption of standalone and consolidated financial statements for year ended March 31, 2026.
• Ordinary: Re-appointment of director retiring by rotation.

Voting Status

• Resolutions were placed to vote via remote e-voting; no physical voting.
• Voting results will be announced and placed on the company's website.

Athena Global Technologies Limited - Trading window closed from Thursday, 01st October, 2026 till the expiry of 48 hours after the declaration of the unaudited financial results for the second quarter and half year ended 30th September 2026

Lease agreement details

• Lease covers 119,526 sq ft on 17th Floor North/South Wing, Phoenix Centaurus, Hyderabad; commencement 27 Nov 2026.
• Annual rent set at ₹11.18 crore, payable monthly ₹93,23,028.
• Lease term five years with option to renew for five years.
• Initial three-year period is a lock-in; rent escalates 15% every three years.
• Lessee identity confidential per LOI; not a related-party transaction.

Financial performance

• Standalone revenue from operations: 805.94 Lakhs.
• Standalone total income: 1178.46 Lakhs.
• Standalone PBT: (3280.35) Lakhs.
• Standalone PAT: (3969.50) Lakhs.
• Consolidated revenue from operations: 1119.66 Lakhs.
• Consolidated total income: 1238.84 Lakhs.
• Consolidated PBT: (2977.24) Lakhs.
• Consolidated exceptional item: 2399.75 Lakhs.
• Consolidated tax expense: 694.52 Lakhs.
• Consolidated PAT: (1332.01) Lakhs.

Dividend & capital allocation

• Dividend for FY2025-26 not recommended due to inadequate profits.
• Transfer to reserves: none.
• No material changes in dividend policy disclosed.
• Athena Global Employee Stock Option Scheme-2019 active.

Capital structure & liquidity

• Authorised share capital: Rs 16 crore; issued: Rs 14.71 crore.
• Total borrowings: Rs 11,476.84 Lakhs; current: Rs 645.91; non-current: Rs 10,830.92.
• Debt/equity ratio: Standalone 0.65; Consolidated 0.85.
• Cash & cash equivalents: Standalone Rs 985.02 Lakhs; Consolidated Rs 1,007.78.
• Current ratio: Standalone 2.81; Consolidated 0.91.
• Promoter stake: 47.52% (M. Satyendra); other promoter holdings disclosed.

Healthcare restructuring & group structure

• Acquired 100% equity in MedleyMed Healthcare Solutions Private Limited.
• Disinvested Medley Medical Solutions Private Limited; becomes direct subsidiary via MedleyMed.
• MedleyMed Healthcare Solutions Private Limited became direct subsidiary; Medley Medical Solutions is step-down.
• Realignment consolidates healthcare ops under single holding entity.

Subsidiaries & group structure

• Subsidiaries: MedleyMed Healthcare Solutions Private Limited; Tutoroot Technologies Private Limited; Athena Global Technologies, Inc.
• Other subsidiaries: MedleyMed Logistics Pvt Ltd; Medley Med, Inc. (foreign).
• UK subsidiary: Athena Global Technologies UK not commenced as of FY2025-26.

Governance & risk management

• Board comprised of six directors; three independent.
• Nine board meetings held in the year.
• Nukala Ashwanth ceased as Independent Director; Rajesh Katragadda appointed Independent Director.
• Gayathri Prithviraj appointed Company Secretary & Compliance Officer.
• Statutory auditors: Ramanatham & Rao; Secretarial auditor: P. S. Rao & Associates.
• LODR-related compliance: delay in Annual Report 2025 led to a Rs 7,080 fine paid.

Employee stock options

• Athena Global Employee Stock Option Scheme-2019: 66,350 options granted in FY2025-26.
• Options vested: 37,838; exercised: 11,588; lapsed: 1,250.
• Exercise price: Rs 60 per share; funds realized: Rs 6.95 lakh.
• KMP granted 1082 equity shares; compliance verified by Secretarial Auditor.

Outlook & strategy

• Strategy focuses on cost discipline and selective client-facing AI investments.
• Growth in healthcare and edtech via MedleyMed and Tutoroot.
• Emphasis on AI, analytics, cloud-native, DevOps to drive margin expansion.
• Targeting ESG initiatives, talent development, and strategic partnerships.

Management commentary & risks

• Management expects gradual earnings improvement via higher-margin engagements.
• Risks include pricing pressure, talent retention, and regulatory changes.
• Management continues to monitor currency and trade policy exposures.

Meeting Details

• Board meeting on 14 August 2026 at the registered office; time not disclosed.

Key Agenda Items

• Consider and approve unaudited standalone and consolidated financial results for Q1 ended 30 June 2026.

Other Notes

• Trading window closed from 01 July 2026 till 48 hours after results for designated persons and connected parties.

Certificate submission status

• RTA has issued a certificate confirming Reg 74(5) compliance for the quarter.

Financial results

• Approved audited standalone and consolidated results for Q4 and FY ended 31 March 2026.

Auditor opinion

• Statutory auditors issued unmodified opinions on standalone and consolidated audited results for FY 2025-26.

Internal auditor appointment

• Appointed M/s. Sarda & Agarwal, Chartered Accountants, as internal auditors for FY 2026-27.
• Appointment effective 30 May 2026, as recommended by the Audit Committee.

Investment approval

• Approved investment up to ₹50 crore in OCDs of Medley Medical Solutions and Tutoroot Technologies.
• Investment may be made in one or more tranches.

Meeting Details

• Board meeting scheduled for 30 May 2026.
• Meeting time was not disclosed.
• Meeting to be held at the registered office of the company.

Key Agenda Items

• Approve audited standalone and consolidated financial results for Q4 and year ended 31 March 2026.

Other Notes

• Trading window closed from 1 April 2026 until 48 hours after results announcement.